Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Torisel Action Date Extended To July 5

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA will use extension to examine new tumor evaluation information submitted by Wyeth.

You may also be interested in...



Wyeth’s Torisel To Launch In July Following FDA Approval

Renal cell carcinoma treatment will compete with Bayer/Onyx’s Nexavar and Pfizer’s Sutent.

Wyeth’s Torisel To Launch In July Following FDA Approval

Renal cell carcinoma treatment will compete with Bayer/Onyx’s Nexavar and Pfizer’s Sutent.

Wyeth Pharmaceuticals U.S. President Geno Germano: An Interview With “The Pink Sheet” DAILY

Exec discusses Wyeth's selling model and how the firm is planning for potential launches this year of products like Pristiq and Torisel.

Related Content

Topics

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel